Auris Medical Holding AG (NASDAQ:EARS)’s share price traded up 3.7% on Tuesday . The stock traded as high as $4.00 and last traded at $3.90, with a volume of 62,511 shares changing hands. The stock had previously closed at $3.76.

A number of brokerages have weighed in on EARS. Zacks Investment Research upgraded shares of Auris Medical Holding AG from a “hold” rating to a “buy” rating and set a $4.50 target price for the company in a research report on Tuesday, July 12th. Leerink Swann reiterated a “buy” rating and set a $12.00 target price on shares of Auris Medical Holding AG in a research report on Wednesday, June 15th. Finally, Jefferies Group reiterated a “buy” rating on shares of Auris Medical Holding AG in a research report on Friday, June 10th.

The firm has a 50-day moving average price of $3.88 and a 200 day moving average price of $3.98. The firm’s market capitalization is $133.88 million.

Auris Medical Holding AG (NASDAQ:EARS) last posted its quarterly earnings results on Wednesday, May 11th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by $0.04. During the same period in the previous year, the firm earned ($0.28) earnings per share. Equities research analysts expect that Auris Medical Holding AG will post ($1.01) EPS for the current fiscal year.

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.